Development of a novel ALK rearrangement screening test for non–small cell lung cancers

Approximately 5–7% of non–small cell lung cancer (NSCLC) cases harbor an anaplastic lymphoma kinase (ALK) fusion gene and may benefit from ALK inhibitor therapy. To detect ALK fusion genes, we developed a novel test using reverse transcription polymerase chain reaction (RT-PCR) for the ALK kinase do...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Lin, Chen, Wan-Li, Cheng, Yi-Chia, Lin, Ming-Ching, Yang, Shu-Ching, Tsai, Hung-Wen, Lin, Chien‐Chung, Su, Wu-Chou, Chow, Nan-Haw, Ho, Chung-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462717/
https://www.ncbi.nlm.nih.gov/pubmed/34559836
http://dx.doi.org/10.1371/journal.pone.0257152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462717/
https://www.ncbi.nlm.nih.gov/pubmed/34559836
http://dx.doi.org/10.1371/journal.pone.0257152

Ejemplares similares